

# General Hardness (GH) Test Solution

## Mars Fishcare North America, Inc.

Chemwatch: 4650-37

Version No: 5.1

Safety Data Sheet (Conforms to Annex II of REACH (1907/2006) - Regulation 2020/878)

Chemwatch Hazard Alert Code: 3

Issue Date: 11/01/2019

Print Date: 05/27/2022

L.REACH.GB-NIR.EN

### SECTION 1 Identification of the substance / mixture and of the company / undertaking

#### 1.1. Product Identifier

Product name	General Hardness (GH) Test Solution
Chemical Name	Not Applicable
Synonyms	Solution ID# 3338
Chemical formula	Not Applicable
Other means of identification	Not Available

#### 1.2. Relevant identified uses of the substance or mixture and uses advised against

Relevant identified uses	Hardness test solution for products 58 and 34.
Uses advised against	Not Applicable

#### 1.3. Details of the supplier of the safety data sheet

Registered company name	Mars Fishcare North America, Inc.
Address	50 E. Hamilton Street, Chalfont PA 18914 United States
Telephone	215 822 8181
Fax	215 997 1290
Website	Not Available
Email	Not Available

#### 1.4. Emergency telephone number

Association / Organisation	ChemTel	CHEMWATCH EMERGENCY RESPONSE
Emergency telephone numbers	1-800-255-3924	+44 20 3901 3542
Other emergency telephone numbers	ChemTel: 1-813-248-0585	+44 808 164 9592

Once connected and if the message is not in your preferred language then please dial 01

### SECTION 2 Hazards identification

#### 2.1. Classification of the substance or mixture

Classification according to regulation (EC) No 1272/2008 [CLP] and amendments [1]	H318 - Serious Eye Damage/Eye Irritation Category 1, H317 - Sensitisation (Skin) Category 1, H351 - Carcinogenicity Category 2, H335 - Specific Target Organ Toxicity - Single Exposure (Respiratory Tract Irritation) Category 3, H315 - Skin Corrosion/Irritation Category 2
Legend:	1. Classified by Chemwatch; 2. Classification drawn from Regulation (EU) No 1272/2008 - Annex VI

#### 2.2. Label elements

Hazard pictogram(s)	
Signal word	Danger

## General Hardness (GH) Test Solution

## Hazard statement(s)

H318	Causes serious eye damage.
H317	May cause an allergic skin reaction.
H351	Suspected of causing cancer.
H335	May cause respiratory irritation.
H315	Causes skin irritation.

## Supplementary statement(s)

Not Applicable

## Precautionary statement(s) General

P101	If medical advice is needed, have product container or label at hand.
P102	Keep out of reach of children.
P103	Read carefully and follow all instructions.

## Precautionary statement(s) Prevention

P201	Obtain special instructions before use.
P271	Use only outdoors or in a well-ventilated area.
P280	Wear protective gloves, protective clothing, eye protection and face protection.
P261	Avoid breathing mist/vapours/spray.
P264	Wash all exposed external body areas thoroughly after handling.
P272	Contaminated work clothing should not be allowed out of the workplace.

## Precautionary statement(s) Response

P305+P351+P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P308+P313	IF exposed or concerned: Get medical advice/ attention.
P310	Immediately call a POISON CENTER/doctor/physician/first aider.
P302+P352	IF ON SKIN: Wash with plenty of water.
P333+P313	If skin irritation or rash occurs: Get medical advice/attention.
P362+P364	Take off contaminated clothing and wash it before reuse.
P304+P340	IF INHALED: Remove person to fresh air and keep comfortable for breathing.

## Precautionary statement(s) Storage

P405	Store locked up.
P403+P233	Store in a well-ventilated place. Keep container tightly closed.

## Precautionary statement(s) Disposal

P501	Dispose of contents/container to authorised hazardous or special waste collection point in accordance with any local regulation.
------	--

## 2.3. Other hazards

Inhalation, skin contact and/or ingestion may produce health damage\*.

Cumulative effects may result following exposure\*.

REACH - Art.57-59: The mixture does not contain Substances of Very High Concern (SVHC) at the SDS print date.

Not Applicable

## SECTION 3 Composition / information on ingredients

## 3.1.Substances

See 'Composition on ingredients' in Section 3.2

## 3.2.Mixtures

## General Hardness (GH) Test Solution

1.CAS No 2.EC No 3.Index No 4.REACH No	%[weight]	Name	Classification according to regulation (EC) No 1272/2008 [CLP] and amendments	SCL / M-Factor	Nanoform Particle Characteristics
1.102-71-6 2.203-049-8 3.Not Available 4.01-2119486482-31-XXXX	10-30	<u>TRIETHANOLAMINE</u>	Skin Corrosion/Irritation Category 2, Serious Eye Damage/Eye Irritation Category 1, Sensitisation (Skin) Category 1, Carcinogenicity Category 2, Specific Target Organ Toxicity - Single Exposure (Respiratory Tract Irritation) Category 3; H315, H318, H317, H351, H335 [1]	Not Available	Not Available
1.64-02-8 2.200-573-9 3.607-428-00-2 4.01-2120070096-59-XXXX 01-2119486762-27-XXXX	1-5	<u>EDTA</u> <u>TETRASODIUM</u> <u>SALT</u>	Acute Toxicity (Oral) Category 4, Serious Eye Damage/Eye Irritation Category 1; H302, H318 [2]	Not Available	Not Available
1.7732-18-5 2.231-791-2 3.Not Available 4.Not Available	>60	<u>DI METERED</u> <u>WATER</u>	Not Applicable	Not Available	Not Available

**Legend:** 1. Classified by Chemwatch; 2. Classification drawn from Regulation (EU) No 1272/2008 - Annex VI; 3. Classification drawn from C&L; \* EU IOELVs available; [e] Substance identified as having endocrine disrupting properties

## SECTION 4 First aid measures

## 4.1. Description of first aid measures

<b>Eye Contact</b>	<p>If this product comes in contact with the eyes:</p> <ul style="list-style-type: none"> <li>Wash out immediately with fresh running water.</li> <li>Ensure complete irrigation of the eye by keeping eyelids apart and away from eye and moving the eyelids by occasionally lifting the upper and lower lids.</li> <li>Seek medical attention without delay; if pain persists or recurs seek medical attention.</li> <li>Removal of contact lenses after an eye injury should only be undertaken by skilled personnel.</li> </ul>
<b>Skin Contact</b>	<p>If skin contact occurs:</p> <ul style="list-style-type: none"> <li>Immediately remove all contaminated clothing, including footwear.</li> <li>Flush skin and hair with running water (and soap if available).</li> <li>Seek medical attention in event of irritation.</li> </ul>
<b>Inhalation</b>	<ul style="list-style-type: none"> <li>If fumes or combustion products are inhaled remove from contaminated area.</li> <li>Lay patient down. Keep warm and rested.</li> <li>Prostheses such as false teeth, which may block airway, should be removed, where possible, prior to initiating first aid procedures.</li> <li>Apply artificial respiration if not breathing, preferably with a demand valve resuscitator, bag-valve mask device, or pocket mask as trained. Perform CPR if necessary.</li> <li>Transport to hospital, or doctor.</li> </ul>
<b>Ingestion</b>	<ul style="list-style-type: none"> <li><b>IF SWALLOWED, REFER FOR MEDICAL ATTENTION, WHERE POSSIBLE, WITHOUT DELAY.</b></li> <li>For advice, contact a Poisons Information Centre or a doctor.</li> <li>Urgent hospital treatment is likely to be needed.</li> <li>In the mean time, qualified first-aid personnel should treat the patient following observation and employing supportive measures as indicated by the patient's condition.</li> <li>If the services of a medical officer or medical doctor are readily available, the patient should be placed in his/her care and a copy of the SDS should be provided. Further action will be the responsibility of the medical specialist.</li> <li>If medical attention is not available on the worksite or surroundings send the patient to a hospital together with a copy of the SDS.</li> </ul> <p><b>Where medical attention is not immediately available or where the patient is more than 15 minutes from a hospital or unless instructed otherwise:</b></p> <ul style="list-style-type: none"> <li><b>INDUCE</b> vomiting with fingers down the back of the throat, <b>ONLY IF CONSCIOUS</b>. Lean patient forward or place on left side (head-down position, if possible) to maintain open airway and prevent aspiration.</li> </ul> <p><b>NOTE:</b> Wear a protective glove when inducing vomiting by mechanical means.</p>

## 4.2 Most important symptoms and effects, both acute and delayed

See Section 11

## 4.3. Indication of any immediate medical attention and special treatment needed

Treat symptomatically.

Continued...

## General Hardness (GH) Test Solution

## SECTION 5 Firefighting measures

## 5.1. Extinguishing media

The product contains a substantial proportion of water, therefore there are no restrictions on the type of extinguishing media which may be used. Choice of extinguishing media should take into account surrounding areas.

Though the material is non-combustible, evaporation of water from the mixture, caused by the heat of nearby fire, may produce floating layers of combustible substances.

In such an event consider:

- foam.
- dry chemical powder.
- carbon dioxide.

## 5.2. Special hazards arising from the substrate or mixture

<b>Fire Incompatibility</b>	None known.
-----------------------------	-------------

## 5.3. Advice for firefighters

<b>Fire Fighting</b>	<ul style="list-style-type: none"> <li>▸ Alert Fire Brigade and tell them location and nature of hazard.</li> <li>▸ Wear breathing apparatus plus protective gloves in the event of a fire.</li> <li>▸ Prevent, by any means available, spillage from entering drains or water courses.</li> <li>▸ Use fire fighting procedures suitable for surrounding area.</li> <li>▸ <b>DO NOT</b> approach containers suspected to be hot.</li> <li>▸ Cool fire exposed containers with water spray from a protected location.</li> <li>▸ If safe to do so, remove containers from path of fire.</li> <li>▸ Equipment should be thoroughly decontaminated after use.</li> </ul>
<b>Fire/Explosion Hazard</b>	<ul style="list-style-type: none"> <li>▸ Non combustible.</li> <li>▸ Not considered to be a significant fire risk.</li> <li>▸ Expansion or decomposition on heating may lead to violent rupture of containers.</li> <li>▸ Decomposes on heating and may produce toxic fumes of carbon monoxide (CO).</li> <li>▸ May emit acrid smoke.</li> </ul> <p>Decomposition may produce toxic fumes of: carbon dioxide (CO<sub>2</sub>) nitrogen oxides (NO<sub>x</sub>) other pyrolysis products typical of burning organic material. May emit poisonous fumes. May emit corrosive fumes.</p>

## SECTION 6 Accidental release measures

## 6.1. Personal precautions, protective equipment and emergency procedures

See section 8

## 6.2. Environmental precautions

See section 12

## 6.3. Methods and material for containment and cleaning up

<b>Minor Spills</b>	<ul style="list-style-type: none"> <li>▸ Clean up all spills immediately.</li> <li>▸ Avoid breathing vapours and contact with skin and eyes.</li> <li>▸ Control personal contact with the substance, by using protective equipment.</li> <li>▸ Contain and absorb spill with sand, earth, inert material or vermiculite.</li> <li>▸ Wipe up.</li> <li>▸ Place in a suitable, labelled container for waste disposal.</li> </ul>
<b>Major Spills</b>	<p>Moderate hazard.</p> <ul style="list-style-type: none"> <li>▸ Clear area of personnel and move upwind.</li> <li>▸ Alert Fire Brigade and tell them location and nature of hazard.</li> <li>▸ Wear breathing apparatus plus protective gloves.</li> <li>▸ Prevent, by any means available, spillage from entering drains or water course.</li> <li>▸ Stop leak if safe to do so.</li> <li>▸ Contain spill with sand, earth or vermiculite.</li> <li>▸ Collect recoverable product into labelled containers for recycling.</li> <li>▸ Neutralise/decontaminate residue (see Section 13 for specific agent).</li> <li>▸ Collect solid residues and seal in labelled drums for disposal.</li> <li>▸ Wash area and prevent runoff into drains.</li> <li>▸ After clean up operations, decontaminate and launder all protective clothing and equipment before storing and re-using.</li> <li>▸ If contamination of drains or waterways occurs, advise emergency services.</li> </ul>

## General Hardness (GH) Test Solution

## 6.4. Reference to other sections

Personal Protective Equipment advice is contained in Section 8 of the SDS.

## SECTION 7 Handling and storage

## 7.1. Precautions for safe handling

Safe handling	<ul style="list-style-type: none"> <li>▶ <b>DO NOT</b> allow clothing wet with material to stay in contact with skin</li> <li>▶ <b>DO NOT USE</b> brass or copper containers / stirrers</li> </ul> <p>Alkanolamines and iron may produced unstable complexes. Monoethanolamine (MEA) and iron form a trisethanolamino-iron complex. This material may spontaneously decompose at temperatures between 130 and 160 degrees C. and is suspected of causing a fire in a nearly empty storage tank containing a "heel" of MEA in contact with carbon steel coils. If steam coil heating is used, low pressure steam in stainless steel coils should be considered. Drum heating should also be reviewed and, where possible, temperatures should be maintained below 130 degrees C.</p> <ul style="list-style-type: none"> <li>▶ Avoid all personal contact, including inhalation.</li> <li>▶ Wear protective clothing when risk of exposure occurs.</li> <li>▶ Use in a well-ventilated area.</li> <li>▶ Avoid contact with moisture.</li> <li>▶ Avoid contact with incompatible materials.</li> <li>▶ <b>When handling, DO NOT eat, drink or smoke.</b></li> <li>▶ Keep containers securely sealed when not in use.</li> <li>▶ Avoid physical damage to containers.</li> <li>▶ Always wash hands with soap and water after handling.</li> <li>▶ Work clothes should be laundered separately. Launder contaminated clothing before re-use.</li> <li>▶ Use good occupational work practice.</li> <li>▶ Observe manufacturer's storage and handling recommendations contained within this SDS.</li> <li>▶ Atmosphere should be regularly checked against established exposure standards to ensure safe working conditions are maintained.</li> </ul>
Fire and explosion protection	See section 5
Other information	<ul style="list-style-type: none"> <li>▶ Store in original containers.</li> <li>▶ Keep containers securely sealed.</li> <li>▶ Store in a cool, dry, well-ventilated area.</li> <li>▶ Store away from incompatible materials and foodstuff containers.</li> <li>▶ Protect containers against physical damage and check regularly for leaks.</li> <li>▶ Observe manufacturer's storage and handling recommendations contained within this SDS.</li> </ul>

## 7.2. Conditions for safe storage, including any incompatibilities

Suitable container	<ul style="list-style-type: none"> <li>▶ Polyethylene or polypropylene container.</li> <li>▶ Packing as recommended by manufacturer.</li> <li>▶ Check all containers are clearly labelled and free from leaks.</li> </ul>
Storage incompatibility	<ul style="list-style-type: none"> <li>▶ Avoid strong acids, bases.</li> </ul>



X — Must not be stored together

O — May be stored together with specific precautions

+ — May be stored together

Note: Depending on other risk factors, compatibility assessment based on the table above may not be relevant to storage situations, particularly where large volumes of dangerous goods are stored and handled. Reference should be made to the Safety Data Sheets for each substance or article and risks assessed accordingly.

## 7.3. Specific end use(s)

See section 1.2

## SECTION 8 Exposure controls / personal protection

## 8.1. Control parameters

Ingredient	DNELs Exposure Pattern Worker	PNECs Compartment
TRIETHANOLAMINE	Dermal 7.5 mg/kg bw/day (Systemic, Chronic) Dermal 140 µg/cm² (Local, Chronic) Inhalation 1 mg/m³ (Local, Chronic)	0.32 mg/L (Water (Fresh)) 0.032 mg/L (Water - Intermittent release) 5.12 mg/L (Water (Marine))

Continued...

## General Hardness (GH) Test Solution

Ingredient	DNELs	PNECs
	Exposure Pattern Worker	Compartment
	Dermal 2.66 mg/kg bw/day (Systemic, Chronic) * Oral 3.3 mg/kg bw/day (Systemic, Chronic) * Dermal 70 µg/cm² (Local, Chronic) * Inhalation 0.4 mg/m³ (Local, Chronic) *	1.7 mg/kg sediment dw (Sediment (Fresh Water)) 0.17 mg/kg sediment dw (Sediment (Marine)) 0.151 mg/kg soil dw (Soil) 10 mg/L (STP)
EDTA TETRASODIUM SALT	Inhalation 1.5 mg/m³ (Local, Chronic) Inhalation 3 mg/m³ (Local, Acute) Oral 25 mg/kg bw/day (Systemic, Chronic) * Inhalation 0.6 mg/m³ (Local, Chronic) * Inhalation 1.2 mg/m³ (Local, Acute) *	2.2 mg/L (Water (Fresh)) 0.22 mg/L (Water - Intermittent release) 1.2 mg/L (Water (Marine)) 0.72 mg/kg soil dw (Soil) 43 mg/L (STP)

\* Values for General Population

## Occupational Exposure Limits (OEL)

## INGREDIENT DATA

Source	Ingredient	Material name	TWA	STEL	Peak	Notes
Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available

Not Applicable

## Emergency Limits

Ingredient	TEEL-1	TEEL-2	TEEL-3
TRIETHANOLAMINE	15 mg/m³	240 mg/m³	1,500 mg/m³
EDTA TETRASODIUM SALT	82 mg/m³	900 mg/m³	5,500 mg/m³
EDTA TETRASODIUM SALT	75 mg/m³	830 mg/m³	5,000 mg/m³

Ingredient	Original IDLH	Revised IDLH
TRIETHANOLAMINE	Not Available	Not Available
EDTA TETRASODIUM SALT	Not Available	Not Available
DI METERED WATER	Not Available	Not Available

## Occupational Exposure Banding

Ingredient	Occupational Exposure Band Rating	Occupational Exposure Band Limit
TRIETHANOLAMINE	E	≤ 0.1 ppm
EDTA TETRASODIUM SALT	E	≤ 0.01 mg/m³

## Notes:

Occupational exposure banding is a process of assigning chemicals into specific categories or bands based on a chemical's potency and the adverse health outcomes associated with exposure. The output of this process is an occupational exposure band (OEB), which corresponds to a range of exposure concentrations that are expected to protect worker health.

## MATERIAL DATA

Odour Safety Factor(OSF) OSF=0.77 (triethanolamine)

Exposed individuals are **NOT** reasonably expected to be warned, by smell, that the Exposure Standard is being exceeded.

Odour Safety Factor (OSF) is determined to fall into either Class C, D or E.

The Odour Safety Factor (OSF) is defined as:

OSF= Exposure Standard (TWA) ppm/ Odour Threshold Value (OTV) ppm

Classification into classes follows:

Class OSF Description

- |   |        |  |
|---|--------|--|
| A | 550    | Over 90% of exposed individuals are aware by smell that the Exposure Standard (TLV-TWA for example) is being reached, even when distracted by working activities |
| B | 26-550 | As "A" for 50-90% of persons being distracted  |
| C | 1-26   | As "A" for less than 50% of persons being distracted   |
| D | 0.18-1 | 10-50% of persons aware of being tested perceive by smell that the Exposure Standard is being reached  |
| E | <0.18  | As "D" for less than 10% of persons aware of being tested  |

## 8.2. Exposure controls

<b>8.2.1. Appropriate engineering controls</b>	Engineering controls are used to remove a hazard or place a barrier between the worker and the hazard. Well-designed engineering controls can be highly effective in protecting workers and will typically be independent of worker interactions to
--	---

Continued...

## General Hardness (GH) Test Solution

provide this high level of protection.

The basic types of engineering controls are:

Process controls which involve changing the way a job activity or process is done to reduce the risk.

Enclosure and/or isolation of emission source which keeps a selected hazard "physically" away from the worker and ventilation that strategically "adds" and "removes" air in the work environment. Ventilation can remove or dilute an air contaminant if designed properly. The design of a ventilation system must match the particular process and chemical or contaminant in use. Employers may need to use multiple types of controls to prevent employee overexposure.

Local exhaust ventilation usually required. If risk of overexposure exists, wear approved respirator. Correct fit is essential to obtain adequate protection. Supplied-air type respirator may be required in special circumstances. Correct fit is essential to ensure adequate protection.

An approved self contained breathing apparatus (SCBA) may be required in some situations.

Provide adequate ventilation in warehouse or closed storage area. Air contaminants generated in the workplace possess varying "escape" velocities which, in turn, determine the "capture velocities" of fresh circulating air required to effectively remove the contaminant.

Type of Contaminant:	Air Speed:
solvent, vapours, degreasing etc., evaporating from tank (in still air).	0.25-0.5 m/s (50-100 f/min.)
aerosols, fumes from pouring operations, intermittent container filling, low speed conveyer transfers, welding, spray drift, plating acid fumes, pickling (released at low velocity into zone of active generation)	0.5-1 m/s (100-200 f/min.)
direct spray, spray painting in shallow booths, drum filling, conveyer loading, crusher dusts, gas discharge (active generation into zone of rapid air motion)	1-2.5 m/s (200-500 f/min.)
grinding, abrasive blasting, tumbling, high speed wheel generated dusts (released at high initial velocity into zone of very high rapid air motion).	2.5-10 m/s (500-2000 f/min.)

Within each range the appropriate value depends on:

Lower end of the range	Upper end of the range
1: Room air currents minimal or favourable to capture	1: Disturbing room air currents
2: Contaminants of low toxicity or of nuisance value only.	2: Contaminants of high toxicity
3: Intermittent, low production.	3: High production, heavy use
4: Large hood or large air mass in motion	4: Small hood-local control only

Simple theory shows that air velocity falls rapidly with distance away from the opening of a simple extraction pipe. Velocity generally decreases with the square of distance from the extraction point (in simple cases). Therefore the air speed at the extraction point should be adjusted, accordingly, after reference to distance from the contaminating source. The air velocity at the extraction fan, for example, should be a minimum of 1-2 m/s (200-400 f/min) for extraction of solvents generated in a tank 2 meters distant from the extraction point. Other mechanical considerations, producing performance deficits within the extraction apparatus, make it essential that theoretical air velocities are multiplied by factors of 10 or more when extraction systems are installed or used.

## 8.2.2. Personal protection



## Eye and face protection

- ▶ Safety glasses with side shields.
- ▶ Chemical goggles.
- ▶ Contact lenses may pose a special hazard; soft contact lenses may absorb and concentrate irritants. A written policy document, describing the wearing of lenses or restrictions on use, should be created for each workplace or task. This should include a review of lens absorption and adsorption for the class of chemicals in use and an account of injury experience. Medical and first-aid personnel should be trained in their removal and suitable equipment should be readily available. In the event of chemical exposure, begin eye irrigation immediately and remove contact lens as soon as practicable. Lens should be removed at the first signs of eye redness or irritation - lens should be removed in a clean environment only after workers have washed hands thoroughly. [CDC NIOSH Current Intelligence Bulletin 59], [AS/NZS 1336 or national equivalent]

## Skin protection

See Hand protection below

## Hands/feet protection

- ▶ Wear chemical protective gloves, e.g. PVC.
- ▶ Wear safety footwear or safety gumboots, e.g. Rubber

**NOTE:**

- ▶ The material may produce skin sensitisation in predisposed individuals. Care must be taken, when removing gloves and other protective equipment, to avoid all possible skin contact.
- ▶ Contaminated leather items, such as shoes, belts and watch-bands should be removed and destroyed.

## Body protection

See Other protection below

## Other protection

- ▶ Overalls.
- ▶ P.V.C apron.
- ▶ Barrier cream.
- ▶ Skin cleansing cream.
- ▶ Eye wash unit.

## General Hardness (GH) Test Solution

**Respiratory protection**

Type AK-P Filter of sufficient capacity. (AS/NZS 1716 & 1715, EN 143:2000 & 149:2001, ANSI Z88 or national equivalent)

**8.2.3. Environmental exposure controls**

See section 12

**SECTION 9 Physical and chemical properties****9.1. Information on basic physical and chemical properties**

<b>Appearance</b>	Dark green alkaline solution with a slight odour; mixes with water.		
<b>Physical state</b>	Liquid	<b>Relative density (Water = 1)</b>	1.056
<b>Odour</b>	Not Available	<b>Partition coefficient n-octanol / water</b>	Not Available
<b>Odour threshold</b>	Not Available	<b>Auto-ignition temperature (°C)</b>	Not Applicable
<b>pH (as supplied)</b>	10.7-11.3	<b>Decomposition temperature</b>	Not Available
<b>Melting point / freezing point (°C)</b>	Not Available	<b>Viscosity (cSt)</b>	Not Available
<b>Initial boiling point and boiling range (°C)</b>	Not Available	<b>Molecular weight (g/mol)</b>	Not Applicable
<b>Flash point (°C)</b>	Not Applicable	<b>Taste</b>	Not Available
<b>Evaporation rate</b>	Not Available	<b>Explosive properties</b>	Not Available
<b>Flammability</b>	Not Applicable	<b>Oxidising properties</b>	Not Available
<b>Upper Explosive Limit (%)</b>	Not Applicable	<b>Surface Tension (dyn/cm or mN/m)</b>	Not Available
<b>Lower Explosive Limit (%)</b>	Not Applicable	<b>Volatile Component (%vol)</b>	Not Available
<b>Vapour pressure (kPa)</b>	Not Available	<b>Gas group</b>	Not Available
<b>Solubility in water</b>	Miscible	<b>pH as a solution (Not Available%)</b>	Not Available
<b>Vapour density (Air = 1)</b>	Not Available	<b>VOC g/L</b>	Not Available
<b>Nanoform Solubility</b>	Not Available	<b>Nanoform Particle Characteristics</b>	Not Available
<b>Particle Size</b>	Not Available		

**9.2. Other information**

Not Available

**SECTION 10 Stability and reactivity**

<b>10.1.Reactivity</b>	See section 7.2
<b>10.2. Chemical stability</b>	<ul style="list-style-type: none"> <li>▶ Unstable in the presence of incompatible materials.</li> <li>▶ Product is considered stable.</li> <li>▶ Hazardous polymerisation will not occur.</li> </ul>
<b>10.3. Possibility of hazardous reactions</b>	See section 7.2
<b>10.4. Conditions to avoid</b>	See section 7.2
<b>10.5. Incompatible materials</b>	See section 7.2
<b>10.6. Hazardous decomposition products</b>	See section 5.3

**SECTION 11 Toxicological information****11.1. Information on toxicological effects**

Continued...



## General Hardness (GH) Test Solution

<b>Inhaled</b>	<p>Inhalation of vapours or aerosols (mists, fumes), generated by the material during the course of normal handling, may be harmful.</p> <p>Limited evidence exists that exposure to the material may produce irreversible damage (other than carcinogenesis, mutagenesis and teratogenesis) following a single exposure by inhalation.</p>
<b>Ingestion</b>	<p>Limited evidence exists that exposure to the material may produce irreversible damage (other than carcinogenesis, mutagenesis and teratogenesis) following a single exposure by swallowing.</p>
<b>Skin Contact</b>	<p>Limited evidence exists that exposure to the material may produce irreversible damage (other than carcinogenesis, mutagenesis and teratogenesis) following a single exposure by skin contact.</p> <p>Toxic effects may result from skin absorption</p> <p>Entry into the blood-stream through, for example, cuts, abrasions, puncture wounds or lesions, may produce systemic injury with harmful effects. Examine the skin prior to the use of the material and ensure that any external damage is suitably protected.</p>
<b>Eye</b>	<p>Evidence exists, or practical experience predicts, that the material may cause eye irritation in a substantial number of individuals and/or may produce significant ocular lesions which are present twenty-four hours or more after instillation into the eye(s) of experimental animals.</p> <p>Repeated or prolonged eye contact may cause inflammation characterised by temporary redness (similar to windburn) of the conjunctiva (conjunctivitis); temporary impairment of vision and/or other transient eye damage/ulceration may occur.</p>
<b>Chronic</b>	<p>Limited evidence suggests that repeated or long-term occupational exposure may produce cumulative health effects involving organs or biochemical systems.</p> <p>On the basis, primarily, of animal experiments, concern has been expressed by at least one classification body that the material may produce carcinogenic or mutagenic effects; in respect of the available information, however, there presently exists inadequate data for making a satisfactory assessment.</p> <p>There exists limited evidence that shows that skin contact with the material is capable either of inducing a sensitisation reaction in a significant number of individuals, and/or of producing positive response in experimental animals.</p> <p>Prolonged or chronic exposure to alkanolamines may result in liver, kidney or nervous system injury. Repeated inhalation may aggravate asthma and inflammatory or fibrotic pulmonary disease.</p> <p>Results of repeated exposure tests with diethanolamine (DEA) in laboratory animals include anaemia (rats) and effects on the kidneys (rats and mice) and liver (mice). DEA produces nervous system injury in dogs and rats. Heart and salivary gland lesions have also been seen in mice treated cutaneously with DEA and in mice receiving DEA in drinking water. Rats given high doses of DEA developed anaemia and testicular lesions.</p> <p>Exaggerated doses of DEA produced heart and nervous system effects in other animals. Changes in other organs were judged to be secondary due to the poor health of animals subjected to extremely high doses of DEA. Rats, rabbits and guinea pigs exposed to high vapour concentrations of volatile monoethanolamine (MEA) (up to 1250 ppm) for periods of up to 5 weeks developed pulmonary, hepatic and renal lesions. Dogs, rats and guinea pigs exposed to 100 ppm MEA for 30 days, became apathetic and developed poor appetites. Animal tests also indicate that inhalation exposure to MEA may result in nervous system injury. All species exposed to airborne MEA experienced dermal effects, varying from ulceration to hair loss probably resulting from contact with the cage.</p> <p>An increased incidence of skeletal variations, suggestive of a slight developmental delay was seen in the fetuses of rats given 1500 mg/kg/day DEA cutaneously; this also produced significant maternal toxicity. No foetal malformations, however, were seen in rats nor in rabbits receiving identical treatment. The foetus of rats given high doses of MEA by gavage, showed an increased rate of embryofoetal death, growth retardation, and some malformations including hydronephrosis and hydroureter. The high doses required to produce these effects bring into question the relevance of this finding to humans. There is some evidence that embryofoetotoxicity and teratogenicity does not occur in rats when MEA is administered by dermal application to the mother.</p> <p>The National Toxicology Program (NTP) concluded that there is clear evidence of liver tumours and some evidence of kidney tumours in mice exposed dermally to DEA over their lifetime. Chronic skin painting studies in mice of both sexes produced liver tumours and an increased incidence of kidney tumours in male mice. The significance of these findings to humans is unclear as DEA is neither genotoxic, mutagenic nor clastogenic, and did not induce tumours in rats or transgenic mice similarly treated. Alkanolamines (especially those containing a secondary amine moiety) may react with nitrites or other nitrosating agents to form carcinogenic N-nitrosamines. Alkanolamines are metabolised by biosynthetic routes to ethanolamine and choline and incorporated into phospholipids. They are excreted predominantly unchanged with a half-life of approximately one week. In the absence of sodium nitrite, no conversion to carcinogenic N-nitrosamines was observed.</p> <p>Diethanolamine competitively inhibits the cellular uptake of choline, in vitro, and hepatic changes in choline homeostasis, consistent with choline deficiency, are observed in vivo.</p> <p>Many amines are potent skin and respiratory sensitisers and certain individuals especially those described as "atopic" (i.e. those predisposed to asthma and other allergic responses) may show allergic reactions when chronically exposed to alkanolamines.</p> <p>In a study with coconut diethanolamide, the National Toxicology Program (Technical Report Series 479), showed clear evidence of carcinogenic activity in male B6C3F1 mice based on increased incidences of hepatic and renal tubule neoplasms and in female B6C3F1 mice based on increased incidences of hepatic neoplasms. There was equivocal evidence of carcinogenic activity in female F344/N rats based on a marginal increase in the incidence of renal tube neoplasms. These increases were associated with the concentration of free diethanolamine present as a contaminant in the diethanolamine condensate. Exposure to rats to coconut oil diethanolamine condensate by dermal application in ethanol for 2 years resulted in epidermal hyperplasia,</p>

## General Hardness (GH) Test Solution

sebaceous gland hyperplasia, hyperkeratosis and parakeratosis in males and females and ulcer in females at the site of application. There were increases in the incidences of chronic inflammation, epithelial hyperplasia, and epithelial ulcer in the forestomach of female rats. The severity of nephropathy in dosed female rats were increased. Exposure of mice to coconut oil diethanolamine condensate by dermal application for 2 years resulted in increased incidences of eosinophilic foci of the liver in males. Increased incidences of epidermal hyperplasia, sebaceous gland hyperplasia, and hyperkeratosis in males and females, ulcer in males, and parakeratosis and inflammation in females at the site of application and of follicular cell hyperplasia in the thyroid gland of males and females, were chemical related.

Parenteral administration of EDTA and its salts in high doses may produce severe renal lesions with tubular necrosis, internal haemorrhage, transient bone marrow depression and life-threatening hypocalcaemia. Prolonged parenteral exposures produce electrolyte imbalance and possible cardiac arrhythmias.

Prolonged or repeated skin contact may result in irritation. EDTA and its metal salts do not permeate the cellular membrane to a significant extent; they remain in the extracellular fluid until excreted. (ILO Encyclopaedia)

NOTE: Conflicting animal test data is available with regard to the teratogenic potential of EDTA sodium salts. Some data indicate that teratogenic effects may occur at extremely high maternal doses.

General Hardness (GH) Test Solution	TOXICITY	IRRITATION
	Not Available	Not Available
TRIETHANOLAMINE	TOXICITY	IRRITATION
	dermal (rat) LD50: >16000 mg/kg <sup>[2]</sup>	Eye (rabbit): 0.1 ml -
	Oral (Rabbit) LD50; 2200 mg/kg <sup>[2]</sup>	Eye (rabbit): 10 mg - mild
		Eye (rabbit): 5.62 mg - SEVERE
		minor conjunctival irritation
		no irritation *
		Skin (human): 15 mg/3d (int)-mild
		Skin (rabbit): 4 h occluded
EDTA TETRASODIUM SALT	TOXICITY	IRRITATION
	Oral (Rat) LD50; 630 mg/kg <sup>[2]</sup>	Eyes (rabbit): 1.9 mg
		Eyes (rabbit): 100 mg/24h-moderate
		Skin (rabbit): 500 mg/24h-moderate
DI METERED WATER	TOXICITY	IRRITATION
	Oral (Rat) LD50; >90000 mg/kg <sup>[2]</sup>	Not Available
<b>Legend:</b>	1. Value obtained from Europe ECHA Registered Substances - Acute toxicity 2. * Value obtained from manufacturer's SDS. Unless otherwise specified data extracted from RTECS - Register of Toxic Effect of chemical Substances	

Lachrymation, diarrhoea, convulsions, urinary tract changes, changes in bladder weight, changes in testicular weight, changes in thymus weight, changes in liver weight, dermatitis after systemic exposure, kidney, ureter, bladder tumours recorded. Equivocal tumourigen by RTECS criteria. Dermal rabbit value quoted above is for occluded patch in male or female animals \* Union Carbide

While it is difficult to generalise about the full range of potential health effects posed by exposure to the many different amine compounds, characterised by those used in the manufacture of polyurethane and polyisocyanurate foams, it is agreed that overexposure to the majority of these materials may cause adverse health effects.

- ▶ Many amine-based compounds can induce histamine liberation, which, in turn, can trigger allergic and other physiological effects, including bronchoconstriction or bronchial asthma and rhinitis.
- ▶ Systemic symptoms include headache, nausea, faintness, anxiety, a decrease in blood pressure, tachycardia (rapid heartbeat), itching, erythema (reddening of the skin), urticaria (hives), and facial edema (swelling). Systemic effects (those affecting the body) that are related to the pharmacological action of amines are usually transient.

Typically, there are four routes of possible or potential exposure: inhalation, skin contact, eye contact, and ingestion.

#### Inhalation:

Inhalation of vapors may, depending upon the physical and chemical properties of the specific product and the degree and length of exposure, result in moderate to severe irritation of the tissues of the nose and throat and can irritate the lungs.

Products with higher vapour pressures have a greater potential for higher airborne concentrations. This increases the probability of worker exposure.

Higher concentrations of certain amines can produce severe respiratory irritation, characterised by nasal discharge, coughing, difficulty in breathing, and chest pains.

Chronic exposure via inhalation may cause headache, nausea, vomiting, drowsiness, sore throat, bronchopneumonia, and possible lung damage. Also, repeated and/or prolonged exposure to some amines may result in liver disorders, jaundice, and liver enlargement. Some amines have been shown to cause kidney, blood, and central nervous system disorders in laboratory animal studies.

While most polyurethane amine catalysts are not sensitizers, some certain individuals may also become sensitized to amines

## General Hardness (GH) Test Solution

and may experience respiratory distress, including asthma-like attacks, whenever they are subsequently exposed to even very small amounts of vapor. Once sensitised, these individuals must avoid any further exposure to amines. Although chronic or repeated inhalation of vapor concentrations below hazardous or recommended exposure limits should not ordinarily affect healthy individuals, chronic overexposure may lead to permanent pulmonary injury, including a reduction in lung function, breathlessness, chronic bronchitis, and immunologic lung disease.

Inhalation hazards are increased when exposure to amine catalysts occurs in situations that produce aerosols, mists, or heated vapors. Such situations include leaks in fitting or transfer lines. Medical conditions generally aggravated by inhalation exposure include asthma, bronchitis, and emphysema.

**Skin Contact:**

Skin contact with amine catalysts poses a number of concerns. Direct skin contact can cause moderate to severe irritation and injury-i.e., from simple redness and swelling to painful blistering, ulceration, and chemical burns. Repeated or prolonged exposure may also result in severe cumulative dermatitis.

Skin contact with some amines may result in allergic sensitisation. Sensitised persons should avoid all contact with amine catalysts. Systemic effects resulting from the absorption of the amines through skin exposure may include headaches, nausea, faintness, anxiety, decrease in blood pressure, reddening of the skin, hives, and facial swelling. These symptoms may be related to the pharmacological action of the amines, and they are usually transient.

**Eye Contact:**

Amine catalysts are alkaline in nature and their vapours are irritating to the eyes, even at low concentrations.

Direct contact with the liquid amine may cause severe irritation and tissue injury, and the "burning" may lead to blindness.

(Contact with solid products may result in mechanical irritation, pain, and corneal injury.)

Exposed persons may experience excessive tearing, burning, conjunctivitis, and corneal swelling.

The corneal swelling may manifest itself in visual disturbances such as blurred or "foggy" vision with a blue tint ("blue haze") and sometimes a halo phenomenon around lights. These symptoms are transient and usually disappear when exposure ceases.

Some individuals may experience this effect even when exposed to concentrations below doses that ordinarily cause respiratory irritation.

**Ingestion:**

The oral toxicity of amine catalysts varies from moderately to very toxic.

Some amines can cause severe irritation, ulceration, or burns of the mouth, throat, esophagus, and gastrointestinal tract.

Material aspirated (due to vomiting) can damage the bronchial tubes and the lungs.

Affected persons also may experience pain in the chest or abdomen, nausea, bleeding of the throat and the gastrointestinal tract, diarrhea, dizziness, thirst, circulatory collapse, coma, and even death.

**Polyurethane Amine Catalysts: Guidelines for Safe Handling and Disposal; Technical Bulletin June 2000  
Alliance for Polyurethanes Industry**

The material may produce severe irritation to the eye causing pronounced inflammation. Repeated or prolonged exposure to irritants may produce conjunctivitis.

The material may cause skin irritation after prolonged or repeated exposure and may produce a contact dermatitis (nonallergic).

This form of dermatitis is often characterised by skin redness (erythema) and swelling epidermis. Histologically there may be intercellular oedema of the spongy layer (spongiosis) and intracellular oedema of the epidermis.

For triethanolamine (and its salts):

**Acute toxicity:** Triethanolamine is of low toxicity by the oral, dermal and inhalation routes of exposure. Oral LD50 values have been shown to range from approximately 5-10 g/kg. The dermal LD50 is greater than 2 g/kg. The inhalation LC50 is greater than a saturated atmosphere

**Repeat Dose Toxicity:** The studies to determine toxicity of triethanolamine from repeated exposure were conducted for a duration of 91 days or 2 years. In both studies the NOAEL was at least 1000 mg/kg. There was no evidence of gross or histopathological change that could be attributed to treatment. Also, triethanolamine was shown to be non-carcinogenic.

**Genetic Toxicity:** Mutation (bacterial); This endpoint has been satisfied by two studies using 4 strains (TA 98, TA 100, TA 1535 and TA 1537) of *Salmonella typhimurium*. Triethanolamine was not mutagenic in any of the tester strains.

Chromosomal aberration (mammalian, *in vitro*) – This endpoint was satisfied by a cytogenetic assay using Chinese hamster lung cells. Triethanolamine did not induce chromosome aberrations in this test system.

**Reproductive Toxicity:** No studies have been conducted to specifically evaluate the effect of triethanolamine on reproductive performance. However, based on consideration of the repeat dose toxicity studies of at least 90 days duration, there were no abnormalities noted in the histopathological examination of reproductive organs. This fact, and the lack of effects on foetal development, allow the conclusion that triethanolamine would not be expected to produce adverse effects to reproductive performance and fertility.

**Developmental Toxicity:** This endpoint was satisfied using a developmental toxicity screening study according to the Chernoff-Kavlock method. Based on the results from this test, triethanolamine does not impair development of the fetus.

A Cosmetic Ingredient Review (CIR) expert panel conducted a review of triethanolamine-containing personal care products

The panel was concerned with the levels of free diethanolamine that could be present as an impurity in TEA or TEA-containing ingredients. The panel stated that the amount of free diethanolamine available must be limited to the present practices of use and concentration of diethanolamine.

The Panel concluded that TEA and 31 related TEA-containing ingredients, are safe when formulated to be nonirritating and when the levels of free diethanolamine do not exceed the prescribed levels. These ingredients should not be used in cosmetic products in which N-nitroso compounds can be formed.

Dermal carcinogenicity studies performed by the NTP on TEA reported equivocal evidence of carcinogenic activity in male mice based on the occurrence of liver hemangiosarcoma, some evidence of carcinogenic activity in female mice based on increased incidences of hepatocellular adenoma, and equivocal evidence of carcinogenic activity in male rats based on a marginal increase in the incidence of renal tubule cell adenoma. It has been hypothesized that TEA may cause liver tumours in mice via a choline-depletion mode of action. Humans are much less sensitive to this deficiency, and these hepatic findings are considered to have little relevance to humans regarding the safety of the use of TEA in personal care products.

The panel was concerned that the potential exists for dermal irritation with the use of products formulated using TEA or TEA-related ingredients. The panel specified that products containing these ingredients must be formulated to be nonirritating.

## General Hardness (GH) Test Solution

	<p>Tertiary alkyl amines such as TEA do not react with N-nitrosating agents to directly form nitrosamines. However, tertiary amines can act as precursors in nitrosamine formation by undergoing nitrosative cleavage. The resultant secondary amine (ie, diethanolamine) can then be N-nitrosated to products that may be carcinogenic. Because of the potential for this process to occur, TEA and TEA-containing ingredients should not be used in cosmetic products in which N-nitroso compounds can be formed.</p> <p>Safety Assessment of Triethanolamine and Triethanolamine-Containing Ingredients as Used in Cosmetics: International Journal of Toxicology (supplement 1) 59S-83S. 2013  <a href="http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.901.4174&amp;rep=rep1&amp;type=pdf">http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.901.4174&amp;rep=rep1&amp;type=pdf</a></p> <p>The substance is classified by IARC as Group 3:  <b>NOT</b> classifiable as to its carcinogenicity to humans.  Evidence of carcinogenicity may be inadequate or limited in animal testing.  <b>NOTE:</b> Substance has been shown to be mutagenic in at least one assay, or belongs to a family of chemicals producing damage or change to cellular DNA.</p>
EDTA TETRASODIUM SALT	<p>* Sigma Aldrich - for the dihydrate  For ethylenediaminetetraacetic acid (EDTA) and its salts:  EDTA is a strong organic acid (approximately 1000 times stronger than acetic acid). It has a high affinity for alkaline-earth ions (for example, calcium and magnesium) and heavy-metal ions (for example, lead and mercury). This affinity generally results in the formation of highly stable and soluble hexadentate chelate complexes. EDTA's ability to complex is used commercially to either promote or inhibit chemical reactions, depending on application.  EDTA and its salts are expected to be absorbed by the lungs and gastrointestinal tract; absorption through the skin is unlikely. In general, EDTA and its salts are mild skin irritants but considered severe eye irritants. The greatest risk in the human body will occur when the EDTA attempts to scavenge the trace metals used and required by the body.  The binding of divalent and trivalent cations by EDTA can cause mineral deficiencies, which seem to be responsible for all of the known pharmacological effects. Sensitivity to the toxic effects of EDTA is, at least in part, related to the deficiency of zinc.  Several short term studies, reported no adverse effects from administering doses up to 5% of EDTA and its salts to lab rodents daily and for several weeks. Only diarrhoea and lowered food consumption were reported in animals given 5% disodium EDTA. However, abnormal effects were seen in animals that were fed mineral deficient diets. Abnormal symptoms were observed in male and female rats fed a low mineral diet (0.54% Ca and 0.013%Fe) with the addition of 0%, 0.5%, or 1% disodium EDTA for 205 days. Rats fed a low percent of disodium EDTA in the diet for short term studies with adequate minerals showed no signs of toxicity. Rats fed 0.5% disodium EDTA for 44-52 weeks were without deleterious effects on weight gain, appetite, activity and appearance. Rats fed 1% disodium EDTA with adequate mineral diet for 220 days showed no evidence of dental erosion.  EDTA and its salts are eliminated from the body, 95% via the kidneys and 5% by the bile, along with the metals and free ionic calcium which was bound in transit through the circulatory system.  Trisodium EDTA was tested in a bioassay for carcinogenicity by the National Cancer Institute. Trisodium EDTA administered to male and female rats at low (3,750 ppm) or high (7,500 ppm) concentrations for 103 weeks produced no compound-related signs of chemical toxicity, and tumor incidence was not related to treatment.  EDTA and its salts should not pose a teratogenic concern based on previous studies in lab rodents. Study results indicate no teratogenic effects are likely in lab rodents at doses up to 1000 mg/kg. Adequate minerals in the diet and administration of tap water prevented possible teratogenic effects of EDTA during pregnancy. Teratogenic effects observed in lab rodents were likely due to animals maintained on deionised water and a semi-purified diet, and housed in nonmetallic caging. Infants and children will unlikely be exposed to high concentrations as in lab rodents.  Rats given 1250 mg/kg or 1500 mg/kg by gavage exhibited more maternal toxicity than the diet group, but produced only 21% malformations in the offspring at the lower dose. The subcutaneously administration of 375 mg/kg was also maternally toxic, but did not result in malformations in the offspring. Differences in toxicity and teratogenicity are probably related to absorption differences and interaction with metals. Disodium EDTA ingested during pregnancy is teratogenic in rats at 2% in the diet and greater.  The maximum human consumption of EDTA and its salts in foods was reported to be in the order of 0.4 mg/kg/day. Infants and children also generally drink tap water instead of deionised or distilled water. Even if young infants were to be fed some solid food, given the characteristics of EDTA and its salts, residues are not likely to be present at concentrations for potential sensitivity.</p>
DI METERED WATER	No significant acute toxicological data identified in literature search.
TRIETHANOLAMINE & EDTA TETRASODIUM SALT	<p>The following information refers to contact allergens as a group and may not be specific to this product.  Contact allergies quickly manifest themselves as contact eczema, more rarely as urticaria or Quincke's oedema. The pathogenesis of contact eczema involves a cell-mediated (T lymphocytes) immune reaction of the delayed type. Other allergic skin reactions, e.g. contact urticaria, involve antibody-mediated immune reactions. The significance of the contact allergen is not simply determined by its sensitisation potential: the distribution of the substance and the opportunities for contact with it are equally important. A weakly sensitising substance which is widely distributed can be a more important allergen than one with stronger sensitising potential with which few individuals come into contact. From a clinical point of view, substances are noteworthy if they produce an allergic test reaction in more than 1% of the persons tested.  Asthma-like symptoms may continue for months or even years after exposure to the material ends. This may be due to a non-allergic condition known as reactive airways dysfunction syndrome (RADS) which can occur after exposure to high levels of highly irritating compound. Main criteria for diagnosing RADS include the absence of previous airways disease in a non-atopic individual, with sudden onset of persistent asthma-like symptoms within minutes to hours of a documented exposure to the irritant. Other criteria for diagnosis of RADS include a reversible airflow pattern on lung function tests, moderate to severe bronchial hyperreactivity on methacholine challenge testing, and the lack of minimal lymphocytic inflammation, without eosinophilia. RADS (or asthma) following an irritating inhalation is an infrequent disorder with rates related to the concentration of and duration of exposure to the irritating substance. On the other hand, industrial bronchitis is a disorder that occurs as a result of exposure due to high concentrations of irritating substance (often particles) and is completely reversible after exposure ceases. The disorder is characterized by difficulty breathing, cough and mucus production.</p>
Acute Toxicity	✗
Carcinogenicity	✓

Continued...

## General Hardness (GH) Test Solution

Skin Irritation/Corrosion	✓	Reproductivity	✗
Serious Eye Damage/Irritation	✓	STOT - Single Exposure	✓
Respiratory or Skin sensitisation	✓	STOT - Repeated Exposure	✗
Mutagenicity	✗	Aspiration Hazard	✗

**Legend:** ✗ – Data either not available or does not fill the criteria for classification  
 ✓ – Data available to make classification

## 11.2.1. Endocrine Disruption Properties

Not Available

## SECTION 12 Ecological information

## 12.1. Toxicity

General Hardness (GH) Test Solution	Endpoint	Test Duration (hr)	Species	Value	Source
	Not Available	Not Available	Not Available	Not Available	Not Available
TRIETHANOLAMINE	Endpoint	Test Duration (hr)	Species	Value	Source
	EC10(ECx)	96h	Algae or other aquatic plants	7.1mg/l	1
	LC50	96h	Fish	11800mg/l	2
	BCF	1008h	Fish	<0.4	7
	EC50	72h	Algae or other aquatic plants	>107<260mg/l	2
	EC50	48h	Crustacea	565.2-658.3mg/l	4
	EC50	96h	Algae or other aquatic plants	169mg/l	1
EDTA TETRASODIUM SALT	Endpoint	Test Duration (hr)	Species	Value	Source
	NOEC(ECx)	72h	Algae or other aquatic plants	0.39mg/l	1
	LC50	96h	Fish	41mg/l	2
	EC50	72h	Algae or other aquatic plants	1.01mg/l	1
	EC50	48h	Crustacea	140mg/l	2
DI METERED WATER	Endpoint	Test Duration (hr)	Species	Value	Source
	Not Available	Not Available	Not Available	Not Available	Not Available

**Legend:** Extracted from 1. IUCLID Toxicity Data 2. Europe ECHA Registered Substances - Ecotoxicological Information - Aquatic Toxicity 4. US EPA, Ecotox database - Aquatic Toxicity Data 5. ECETOC Aquatic Hazard Assessment Data 6. NITE (Japan) - Bioconcentration Data 7. METI (Japan) - Bioconcentration Data 8. Vendor Data

**DO NOT** discharge into sewer or waterways.

## 12.2. Persistence and degradability

Ingredient	Persistence: Water/Soil	Persistence: Air
TRIETHANOLAMINE	LOW	LOW
DI METERED WATER	LOW	LOW

## 12.3. Bioaccumulative potential

Ingredient	Bioaccumulation
TRIETHANOLAMINE	LOW (BCF = 3.9)

## 12.4. Mobility in soil

Ingredient	Mobility
TRIETHANOLAMINE	LOW (KOC = 10)

## 12.5. Results of PBT and vPvB assessment

Continued...

## General Hardness (GH) Test Solution

	P	B	T
Relevant available data	Not Available	Not Available	Not Available
PBT	✗	✗	✗
vPvB	✗	✗	✗
PBT Criteria fulfilled?	No		
vPvB	No		

## 12.6. Endocrine Disruption Properties

Not Available

## 12.7. Other adverse effects

Not Available

## SECTION 13 Disposal considerations

## 13.1. Waste treatment methods

Product / Packaging disposal	<ul style="list-style-type: none"> <li>Recycle wherever possible.</li> <li>Consult manufacturer for recycling options or consult local or regional waste management authority for disposal if no suitable treatment or disposal facility can be identified.</li> <li>Dispose of by: burial in a land-fill specifically licensed to accept chemical and / or pharmaceutical wastes or incineration in a licensed apparatus (after admixture with suitable combustible material).</li> <li>Decontaminate empty containers. Observe all label safeguards until containers are cleaned and destroyed.</li> <li>Containers may still present a chemical hazard/ danger when empty.</li> <li>Return to supplier for reuse/ recycling if possible.</li> </ul> <p>Otherwise:</p> <ul style="list-style-type: none"> <li>If container can not be cleaned sufficiently well to ensure that residuals do not remain or if the container cannot be used to store the same product, then puncture containers, to prevent re-use, and bury at an authorised landfill.</li> <li>Where possible retain label warnings and SDS and observe all notices pertaining to the product.</li> </ul>
Waste treatment options	Not Available
Sewage disposal options	Not Available

## SECTION 14 Transport information

## Labels Required

Marine Pollutant	NO
HAZCHEM	Not Applicable

## Land transport (ADR): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS

14.1. UN number	Not Applicable	
14.2. UN proper shipping name	Not Applicable	
14.3. Transport hazard class(es)	Class	Not Applicable
	Subrisk	Not Applicable
14.4. Packing group	Not Applicable	
14.5. Environmental hazard	Not Applicable	
14.6. Special precautions for user	Hazard identification (Kemler)	Not Applicable
	Classification code	Not Applicable
	Hazard Label	Not Applicable
	Special provisions	Not Applicable
	Limited quantity	Not Applicable
	Tunnel Restriction Code	Not Applicable



## General Hardness (GH) Test Solution

## Air transport (ICAO-IATA / DGR): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS

14.1. UN number	Not Applicable	
14.2. UN proper shipping name	Not Applicable	
14.3. Transport hazard class(es)	ICAO/IATA Class	Not Applicable
	ICAO / IATA Subrisk	Not Applicable
	ERG Code	Not Applicable
14.4. Packing group	Not Applicable	
14.5. Environmental hazard	Not Applicable	
14.6. Special precautions for user	Special provisions	Not Applicable
	Cargo Only Packing Instructions	Not Applicable
	Cargo Only Maximum Qty / Pack	Not Applicable
	Passenger and Cargo Packing Instructions	Not Applicable
	Passenger and Cargo Maximum Qty / Pack	Not Applicable
	Passenger and Cargo Limited Quantity Packing Instructions	Not Applicable
	Passenger and Cargo Limited Maximum Qty / Pack	Not Applicable

## Sea transport (IMDG-Code / GGVSee): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS

14.1. UN number	Not Applicable	
14.2. UN proper shipping name	Not Applicable	
14.3. Transport hazard class(es)	IMDG Class	Not Applicable
	IMDG Subrisk	Not Applicable
14.4. Packing group	Not Applicable	
14.5. Environmental hazard	Not Applicable	
14.6. Special precautions for user	EMS Number	Not Applicable
	Special provisions	Not Applicable
	Limited Quantities	Not Applicable

## Inland waterways transport (ADN): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS

14.1. UN number	Not Applicable	
14.2. UN proper shipping name	Not Applicable	
14.3. Transport hazard class(es)	Not Applicable	Not Applicable
14.4. Packing group	Not Applicable	
14.5. Environmental hazard	Not Applicable	
14.6. Special precautions for user	Classification code	Not Applicable
	Special provisions	Not Applicable
	Limited quantity	Not Applicable
	Equipment required	Not Applicable
	Fire cones number	Not Applicable

## 14.7. Transport in bulk according to Annex II of MARPOL and the IBC code

Not Applicable

## 14.8. Transport in bulk in accordance with MARPOL Annex V and the IMSBC Code

Product name	Group
--------------	-------

Continued...

## General Hardness (GH) Test Solution

Product name	Group
TRIETHANOLAMINE	Not Available
EDTA TETRASODIUM SALT	Not Available
DI METERED WATER	Not Available

## 14.9. Transport in bulk in accordance with the ICG Code

Product name	Ship Type
TRIETHANOLAMINE	Not Available
EDTA TETRASODIUM SALT	Not Available
DI METERED WATER	Not Available

## SECTION 15 Regulatory information

## 15.1. Safety, health and environmental regulations / legislation specific for the substance or mixture

## TRIETHANOLAMINE is found on the following regulatory lists

EU European Chemicals Agency (ECHA) Community Rolling Action Plan (CoRAP) List of Substances

Europe EC Inventory

European Union - European Inventory of Existing Commercial Chemical Substances (EINECS)

International Agency for Research on Cancer (IARC) - Agents Classified by the IARC Monographs

## EDTA TETRASODIUM SALT is found on the following regulatory lists

Europe EC Inventory

European Union - European Inventory of Existing Commercial Chemical Substances (EINECS)

European Union (EU) Regulation (EC) No 1272/2008 on Classification, Labelling and Packaging of Substances and Mixtures - Annex VI

## DI METERED WATER is found on the following regulatory lists

Europe EC Inventory

European Union - European Inventory of Existing Commercial Chemical Substances (EINECS)

This safety data sheet is in compliance with the following EU legislation and its adaptations - as far as applicable - : Directives 98/24/EC, - 92/85/EEC, - 94/33/EC, - 2008/98/EC, - 2010/75/EU; Commission Regulation (EU) 2020/878; Regulation (EC) No 1272/2008 as updated through ATPs.

## 15.2. Chemical safety assessment

No Chemical Safety Assessment has been carried out for this substance/mixture by the supplier.

## ECHA SUMMARY

Ingredient	CAS number	Index No	ECHA Dossier
TRIETHANOLAMINE	102-71-6	Not Available	01-2119486482-31-XXXX

Harmonisation (C&L Inventory)	Hazard Class and Category Code(s)	Pictograms Signal Word Code(s)	Hazard Statement Code(s)
1	Not Classified	Not Available	Not Available
2	Eye Dam. 1; Repr. 2; Acute Tox. 4; STOT RE 2; STOT SE 3; STOT SE 3; Met. Corr. 1; STOT RE 2; STOT RE 2; STOT SE 3; STOT SE 3; STOT SE 3; STOT RE 2; STOT RE 2; STOT SE 3; STOT RE 2; Acute Tox. 4; Acute Tox. 4; STOT SE 3; STOT SE 3	GHS08; GHS05; Dgr	H318; H361; H302; H373; H335; H317; H290; H312; H332; H314; H334

Harmonisation Code 1 = The most prevalent classification. Harmonisation Code 2 = The most severe classification.

Ingredient	CAS number	Index No	ECHA Dossier
EDTA TETRASODIUM SALT	64-02-8	607-428-00-2	01-2120070096-59-XXXX 01-2119486762-27-XXXX

Harmonisation (C&L Inventory)	Hazard Class and Category Code(s)	Pictograms Signal Word Code(s)	Hazard Statement Code(s)
1	Acute Tox. 4; Eye Dam. 1	GHS05; Dgr	H302; H318
2	Acute Tox. 4; Eye Dam. 1; Skin Irrit. 2; STOT SE 3; Acute Tox. 4; STOT SE 3; STOT SE 3	GHS05; Dgr	H302; H318; H315; H335; H332

Harmonisation Code 1 = The most prevalent classification. Harmonisation Code 2 = The most severe classification.

Continued...



## General Hardness (GH) Test Solution

Harmonisation (C&L Inventory)	Hazard Class and Category Code(s)	Pictograms Signal Word Code(s)	Hazard Statement Code(s)
1	Acute Tox. 4; Skin Irrit. 2; Eye Irrit. 2; STOT SE 3	GHS07; Wng	H302; H315; H319; H335
2	Acute Tox. 4; Skin Irrit. 2; STOT SE 3; Eye Dam. 1; Acute Tox. 4; STOT RE 2; STOT SE 3; Aquatic Chronic 2; STOT RE 2; STOT SE 3	GHS05; Dgr; GHS08; GHS09	H302; H315; H335; H318; H332; H373; H411
1	Acute Tox. 4; Eye Dam. 1	GHS05; Dgr	H302; H318
2	Acute Tox. 4; Eye Dam. 1	GHS05; Dgr	H302; H318; H315; H335
1	Acute Tox. 4; Eye Dam. 1	GHS05; Dgr	H302; H318
2	Acute Tox. 4; Eye Dam. 1; Acute Tox. 4; STOT RE 2; Acute Tox. 2; STOT RE 2; STOT RE 2; STOT SE 2; STOT RE 2; STOT RE 2; Met. Corr. 1; STOT RE 2; Skin Irrit. 2; Acute Tox. 4; Carc. 2; STOT SE 3; STOT RE 2; STOT RE 2	GHS05; Dgr; GHS08	H302; H318; H332; H373; H371; H315; H312; H317; H351; H335

Harmonisation Code 1 = The most prevalent classification. Harmonisation Code 2 = The most severe classification.

Ingredient	CAS number	Index No	ECHA Dossier
DI METERED WATER	7732-18-5	Not Available	Not Available

Harmonisation (C&L Inventory)	Hazard Class and Category Code(s)	Pictograms Signal Word Code(s)	Hazard Statement Code(s)
1	Not Classified	Not Available	Not Available
2	Flam. Liq. 3; Acute Tox. 3; Eye Irrit. 2; Aquatic Chronic 2	GHS05; Dgr; GHS02; GHS06	H318; H226; H314; H301; H411

Harmonisation Code 1 = The most prevalent classification. Harmonisation Code 2 = The most severe classification.

## National Inventory Status

National Inventory	Status
Australia - AIIC / Australia Non-Industrial Use	Yes
Canada - DSL	Yes
Canada - NDSL	No (TRIETHANOLAMINE; EDTA TETRASODIUM SALT; DI METERED WATER)
China - IECSC	Yes
Europe - EINEC / ELINCS / NLP	Yes
Japan - ENCS	Yes
Korea - KECI	Yes
New Zealand - NZIoC	Yes
Philippines - PICCS	Yes
USA - TSCA	Yes
Taiwan - TCSI	Yes
Mexico - INSQ	Yes
Vietnam - NCI	Yes
Russia - FBEPH	Yes
<b>Legend:</b>	Yes = All CAS declared ingredients are on the inventory No = One or more of the CAS listed ingredients are not on the inventory. These ingredients may be exempt or will require registration.

## SECTION 16 Other information

Revision Date	11/01/2019
Initial Date	09/13/2005

## Full text Risk and Hazard codes

H226	Flammable liquid and vapour.
H290	May be corrosive to metals.
H301	Toxic if swallowed.

Continued...

## General Hardness (GH) Test Solution

H302	Harmful if swallowed.
H312	Harmful in contact with skin.
H314	Causes severe skin burns and eye damage.
H319	Causes serious eye irritation.
H332	Harmful if inhaled.
H334	May cause allergy or asthma symptoms or breathing difficulties if inhaled.
H361	Suspected of damaging fertility or the unborn child.
H371	May cause damage to organs.
H373	May cause damage to organs through prolonged or repeated exposure.
H411	Toxic to aquatic life with long lasting effects.

## SDS Version Summary

Version	Date of Update	Sections Updated
3.1	10/04/2005	Supplier Information, Synonyms, Use
5.1	11/01/2019	One-off system update. NOTE: This may or may not change the GHS classification

## Other information

Classification of the preparation and its individual components has drawn on official and authoritative sources as well as independent review by the Chemwatch Classification committee using available literature references.

The SDS is a Hazard Communication tool and should be used to assist in the Risk Assessment. Many factors determine whether the reported Hazards are Risks in the workplace or other settings. Risks may be determined by reference to Exposures Scenarios. Scale of use, frequency of use and current or available engineering controls must be considered.

For detailed advice on Personal Protective Equipment, refer to the following EU CEN Standards:

EN 166 Personal eye-protection

EN 340 Protective clothing

EN 374 Protective gloves against chemicals and micro-organisms

EN 13832 Footwear protecting against chemicals

EN 133 Respiratory protective devices

This document is copyright.

Apart from any fair dealing for the purposes of private study, research, review or criticism, as permitted under the Copyright Act, no part may be reproduced by any process without written permission from CHEMWATCH.

TEL (+61 3) 9572 4700.